Alastair D Hay1, Kate Birnie2, John Busby2, Brendan Delaney3, Harriet Downing1, Jan Dudley4, Stevo Durbaba5, Margaret Fletcher6,7, Kim Harman1, William Hollingworth2, Kerenza Hood8, Robin Howe9, Michael Lawton2, Catherine Lisles8, Paul Little10, Alasdair MacGowan11, Kathryn O'Brien12, Timothy Pickles8, Kate Rumsby10, Jonathan Ac Sterne2, Emma Thomas-Jones8, Judith van der Voort13, Cherry-Ann Waldron8, Penny Whiting2, Mandy Wootton9, Christopher C Butler12,14. 1. Centre for Academic Primary Care, National Institute for Health Research (NIHR) School of Primary Care Research, School of Social and Community Medicine, University of Bristol, Bristol, UK. 2. School of Social and Community Medicine, University of Bristol, Bristol, UK. 3. Department of Primary Care and Public Health Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. 4. Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK. 5. Department of Primary Care and Public Health Sciences, Division of Health and Social Care Research, King's College London, London, UK. 6. Centre for Health and Clinical Research, University of the West of England, Bristol, UK. 7. South West Medicines for Children Local Research Network, University Hospitals Bristol NHS Foundation Trust, Bristol, UK. 8. South East Wales Trials Unit (SEWTU), Institute for Translation, Innovation, Methodology and Engagement, School of Medicine, Cardiff University, Cardiff, UK. 9. Specialist Antimicrobial Chemotherapy Unit, Public Health Wales Microbiology Cardiff, University Hospital Wales, Cardiff, UK. 10. Primary Care and Population Sciences Division, University of Southampton, Southampton, UK. 11. Southmead Hospital, North Bristol NHS Trust, Bristol, UK. 12. Cochrane Institute of Primary Care & Public Health, School of Medicine, Cardiff University, Cardiff, UK. 13. Department of Paediatrics and Child Health, University Hospital of Wales, Cardiff, UK. 14. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Abstract
BACKGROUND: It is not clear which young children presenting acutely unwell to primary care should be investigated for urinary tract infection (UTI) and whether or not dipstick testing should be used to inform antibiotic treatment. OBJECTIVES: To develop algorithms to accurately identify pre-school children in whom urine should be obtained; assess whether or not dipstick urinalysis provides additional diagnostic information; and model algorithm cost-effectiveness. DESIGN: Multicentre, prospective diagnostic cohort study. SETTING AND PARTICIPANTS: Children < 5 years old presenting to primary care with an acute illness and/or new urinary symptoms. METHODS: One hundred and seven clinical characteristics (index tests) were recorded from the child's past medical history, symptoms, physical examination signs and urine dipstick test. Prior to dipstick results clinician opinion of UTI likelihood ('clinical diagnosis') and urine sampling and treatment intentions ('clinical judgement') were recorded. All index tests were measured blind to the reference standard, defined as a pure or predominant uropathogen cultured at ≥ 10(5) colony-forming units (CFU)/ml in a single research laboratory. Urine was collected by clean catch (preferred) or nappy pad. Index tests were sequentially evaluated in two groups, stratified by urine collection method: parent-reported symptoms with clinician-reported signs, and urine dipstick results. Diagnostic accuracy was quantified using area under receiver operating characteristic curve (AUROC) with 95% confidence interval (CI) and bootstrap-validated AUROC, and compared with the 'clinician diagnosis' AUROC. Decision-analytic models were used to identify optimal urine sampling strategy compared with 'clinical judgement'. RESULTS: A total of 7163 children were recruited, of whom 50% were female and 49% were < 2 years old. Culture results were available for 5017 (70%); 2740 children provided clean-catch samples, 94% of whom were ≥ 2 years old, with 2.2% meeting the UTI definition. Among these, 'clinical diagnosis' correctly identified 46.6% of positive cultures, with 94.7% specificity and an AUROC of 0.77 (95% CI 0.71 to 0.83). Four symptoms, three signs and three dipstick results were independently associated with UTI with an AUROC (95% CI; bootstrap-validated AUROC) of 0.89 (0.85 to 0.95; validated 0.88) for symptoms and signs, increasing to 0.93 (0.90 to 0.97; validated 0.90) with dipstick results. Nappy pad samples were provided from the other 2277 children, of whom 82% were < 2 years old and 1.3% met the UTI definition. 'Clinical diagnosis' correctly identified 13.3% positive cultures, with 98.5% specificity and an AUROC of 0.63 (95% CI 0.53 to 0.72). Four symptoms and two dipstick results were independently associated with UTI, with an AUROC of 0.81 (0.72 to 0.90; validated 0.78) for symptoms, increasing to 0.87 (0.80 to 0.94; validated 0.82) with the dipstick findings. A high specificity threshold for the clean-catch model was more accurate and less costly than, and as effective as, clinical judgement. The additional diagnostic utility of dipstick testing was offset by its costs. The cost-effectiveness of the nappy pad model was not clear-cut. CONCLUSIONS: Clinicians should prioritise the use of clean-catch sampling as symptoms and signs can cost-effectively improve the identification of UTI in young children where clean catch is possible. Dipstick testing can improve targeting of antibiotic treatment, but at a higher cost than waiting for a laboratory result. Future research is needed to distinguish pathogens from contaminants, assess the impact of the clean-catch algorithm on patient outcomes, and the cost-effectiveness of presumptive versus dipstick versus laboratory-guided antibiotic treatment. FUNDING: The National Institute for Health Research Health Technology Assessment programme.
BACKGROUND: It is not clear which young children presenting acutely unwell to primary care should be investigated for urinary tract infection (UTI) and whether or not dipstick testing should be used to inform antibiotic treatment. OBJECTIVES: To develop algorithms to accurately identify pre-school children in whom urine should be obtained; assess whether or not dipstick urinalysis provides additional diagnostic information; and model algorithm cost-effectiveness. DESIGN: Multicentre, prospective diagnostic cohort study. SETTING AND PARTICIPANTS: Children < 5 years old presenting to primary care with an acute illness and/or new urinary symptoms. METHODS: One hundred and seven clinical characteristics (index tests) were recorded from the child's past medical history, symptoms, physical examination signs and urine dipstick test. Prior to dipstick results clinician opinion of UTI likelihood ('clinical diagnosis') and urine sampling and treatment intentions ('clinical judgement') were recorded. All index tests were measured blind to the reference standard, defined as a pure or predominant uropathogen cultured at ≥ 10(5) colony-forming units (CFU)/ml in a single research laboratory. Urine was collected by clean catch (preferred) or nappy pad. Index tests were sequentially evaluated in two groups, stratified by urine collection method: parent-reported symptoms with clinician-reported signs, and urine dipstick results. Diagnostic accuracy was quantified using area under receiver operating characteristic curve (AUROC) with 95% confidence interval (CI) and bootstrap-validated AUROC, and compared with the 'clinician diagnosis' AUROC. Decision-analytic models were used to identify optimal urine sampling strategy compared with 'clinical judgement'. RESULTS: A total of 7163 children were recruited, of whom 50% were female and 49% were < 2 years old. Culture results were available for 5017 (70%); 2740 children provided clean-catch samples, 94% of whom were ≥ 2 years old, with 2.2% meeting the UTI definition. Among these, 'clinical diagnosis' correctly identified 46.6% of positive cultures, with 94.7% specificity and an AUROC of 0.77 (95% CI 0.71 to 0.83). Four symptoms, three signs and three dipstick results were independently associated with UTI with an AUROC (95% CI; bootstrap-validated AUROC) of 0.89 (0.85 to 0.95; validated 0.88) for symptoms and signs, increasing to 0.93 (0.90 to 0.97; validated 0.90) with dipstick results. Nappy pad samples were provided from the other 2277 children, of whom 82% were < 2 years old and 1.3% met the UTI definition. 'Clinical diagnosis' correctly identified 13.3% positive cultures, with 98.5% specificity and an AUROC of 0.63 (95% CI 0.53 to 0.72). Four symptoms and two dipstick results were independently associated with UTI, with an AUROC of 0.81 (0.72 to 0.90; validated 0.78) for symptoms, increasing to 0.87 (0.80 to 0.94; validated 0.82) with the dipstick findings. A high specificity threshold for the clean-catch model was more accurate and less costly than, and as effective as, clinical judgement. The additional diagnostic utility of dipstick testing was offset by its costs. The cost-effectiveness of the nappy pad model was not clear-cut. CONCLUSIONS: Clinicians should prioritise the use of clean-catch sampling as symptoms and signs can cost-effectively improve the identification of UTI in young children where clean catch is possible. Dipstick testing can improve targeting of antibiotic treatment, but at a higher cost than waiting for a laboratory result. Future research is needed to distinguish pathogens from contaminants, assess the impact of the clean-catch algorithm on patient outcomes, and the cost-effectiveness of presumptive versus dipstick versus laboratory-guided antibiotic treatment. FUNDING: The National Institute for Health Research Health Technology Assessment programme.
Authors: Christopher C Butler; Kathryn O'Brien; Timothy Pickles; Kerenza Hood; Mandy Wootton; Robin Howe; Cherry-Ann Waldron; Emma Thomas-Jones; William Hollingworth; Paul Little; Judith Van Der Voort; Jan Dudley; Kate Rumsby; Harriet Downing; Kim Harman; Alastair D Hay Journal: Br J Gen Pract Date: 2015-04 Impact factor: 5.386
Authors: Christopher C Butler; Jonathan Ac Sterne; Michael Lawton; Kathryn O'Brien; Mandy Wootton; Kerenza Hood; William Hollingworth; Paul Little; Brendan C Delaney; Judith van der Voort; Jan Dudley; Kate Birnie; Timothy Pickles; Cherry-Ann Waldron; Harriet Downing; Emma Thomas-Jones; Catherine Lisles; Kate Rumsby; Stevo Durbaba; Penny Whiting; Kim Harman; Robin Howe; Alasdair MacGowan; Margaret Fletcher; Alastair D Hay Journal: Br J Gen Pract Date: 2016-07 Impact factor: 5.386
Authors: Brian E Jones; Yaman G Mkhaimer; Laureano J Rangel; Maroun Chedid; Phillip J Schulte; Alaa K Mohamed; Reem M Neal; Dalia Zubidat; Amarjyot K Randhawa; Christian Hanna; Adriana V Gregory; Timothy L Kline; Ziad M Zoghby; Sarah R Senum; Peter C Harris; Vicente E Torres; Fouad T Chebib Journal: Kidney360 Date: 2021-12-07
Authors: Megan Rose Williams; Giles Greene; Gurudutt Naik; Kathryn Hughes; Christopher C Butler; Alastair D Hay Journal: Br J Gen Pract Date: 2018-01-15 Impact factor: 5.386
Authors: William Hollingworth; John Busby; Christopher C Butler; Kathryn O'Brien; Jonathan A C Sterne; Kerenza Hood; Paul Little; Michael Lawton; Kate Birnie; Emma Thomas-Jones; Kim Harman; Alastair D Hay Journal: Value Health Date: 2017-02-22 Impact factor: 5.725
Authors: Kate Birnie; Alastair D Hay; Mandy Wootton; Robin Howe; Alasdair MacGowan; Penny Whiting; Michael Lawton; Brendan Delaney; Harriet Downing; Jan Dudley; William Hollingworth; Catherine Lisles; Paul Little; Kathryn O'Brien; Timothy Pickles; Kate Rumsby; Emma Thomas-Jones; Judith Van der Voort; Cherry-Ann Waldron; Kim Harman; Kerenza Hood; Christopher C Butler; Jonathan A C Sterne Journal: PLoS One Date: 2017-02-15 Impact factor: 3.240
Authors: Alastair D Hay; Niamh M Redmond; Sophie Turnbull; Hannah Christensen; Hannah Thornton; Paul Little; Matthew Thompson; Brendan Delaney; Andrew M Lovering; Peter Muir; John P Leeming; Barry Vipond; Beth Stuart; Tim J Peters; Peter S Blair Journal: Lancet Respir Med Date: 2016-09-01 Impact factor: 30.700